TheraRadar
Data updated: May 26, 2026

CEFPODOXIME PROXETIL

Infectious Disease Approved 2002-05-31

CEFPODOXIME PROXETIL is indicated for the treatment of Acute Otitis Media; Pharyngitis; Tonsillitis; Community-Acquired Pneumonia; Acute Bacterial Exacerbation of Chronic Bronchitis.

Source: FDA Label • ANDA REPOSITORY
8
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-05-31
Routes
ORAL
Dosage Forms
TABLET, FOR SUSPENSION

CEFPODOXIME PROXETIL Approval History

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
40 FDA actions from 2002 to 2022
May 2022 ORIGINAL
Update
Oct 2015 SUPPL
Label · Labeling
Sep 2015 SUPPL
Label · Labeling

What CEFPODOXIME PROXETIL Treats

5 indications

CEFPODOXIME PROXETIL is approved for 5 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acute Otitis Media
  • Pharyngitis
  • Tonsillitis
  • Community-Acquired Pneumonia
  • Acute Bacterial Exacerbation of Chronic Bronchitis
Source: FDA Label

CEFPODOXIME PROXETIL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFPODOXIME PROXETIL

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZITHROMYCIN
AZITHROMYCIN
5 shared
Sun Pharma
Shared indications:
Acute Bacterial Exacerbation of Chronic BronchitisAcute Otitis MediaCommunity-Acquired Pneumonia +2 more
CLARITHROMYCIN
CLARITHROMYCIN
5 shared
MPP PHARMA
Shared indications:
Acute Bacterial Exacerbation of Chronic BronchitisCommunity-Acquired PneumoniaPharyngitis +2 more
CEFUROXIME AXETIL
CEFUROXIME AXETIL
3 shared
Lupin
Shared indications:
PharyngitisTonsillitisAcute Otitis Media
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT03491748 CS0282-2017-0001 1010452 Ph 1 completed A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFPODOXIME PROXETIL FDA Label Details

Indications & Usage

FDA Label (PDF)

CEFPODOXIME PROXETIL is indicated for the treatment of Acute Otitis Media; Pharyngitis; Tonsillitis; Community-Acquired Pneumonia; Acute Bacterial Exacerbation of Chronic Bronchitis.

Looking for the branded version?

BANAN

Full clinical data, patents, trials, and competitive landscape for cefpodoxime proxetil.

See BANAN

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.